First patients to receive new cancer drug in groundbreaking safety trial
Disease control
Recruiting now
This is the first-ever study in people for a new drug called EPI-326. It aims to find a safe dose and see how the body handles the drug in patients with advanced lung cancer (with a specific genetic change called EGFR mutation) or advanced head and neck cancer. The main goal is t…
Phase: PHASE1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC